G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells

Clinical and Experimental Metastasis

Volumn 16, Issue 6, 1998, Pages 551-558

  Pei, Xin Hai ^a   Nakanishi, Yoichi ^a   Takayama, Koichi ^a   Bai, Fen ^a   Kawasaki, Masayuki ^a   Hara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

G CSF; Invasion; Lung cancer; uPA

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; UROKINASE;

ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DENSITOMETRY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER;

DOSE-RESPONSE RELATIONSHIP, DRUG; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PLASMINOGEN INACTIVATORS; POLYMERASE CHAIN REACTION; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; RNA, MESSENGER; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032417651     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006546402703     Document Type: Article

References (27)

1. Testa JE and Quigley JP, 1990. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev, 9, 353-67.
2. Mignatti P and Rifkin DB, 1993, Biology and biochemistry of proteinases in tumor invasion. Physiol Rev, 73, 161-95.
3. Cubellis MV, Wun TC and Blasi F, 1990, Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J, 9, 1079-85.
4. Petersen LC, Lund LR, Nielsen LS, et al, 1988, One chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem, 263, 11189-95.
5. Harmenberg J, Hoglund M and Hellstrom-Lindberg E, 1994, G- and GM-CSF in oncology and oncological haematology. Eur J Haematol, 52, 1-28.
6. Thacker JD, Dedhar S and Hogge DE, 1994, The effect of GM-CSF and G-CSF on the growth of human osteosarcoma cells in vitro and in vivo. Int J Cancer, 56, 236-43.
7. Pei XH, Nakanishi Y, Takayama K, et al. 1996, Granulocyte-colony stimulating factor promotes invasion by human lung cancer cell lines in vitro. Clin Exp Metastasis, 14, 351-7.
8. Heussen C and Dowdle EB, 1980, Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Analyt Biochem, 102, 196-202.
9. Faber-Elman A, Mishkin R and Schwartz M, 1995, Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor-α and interleukin-1β through signal transduction pathways. J Neurochem, 65, 1524-35.
10. Nakajima-Iijima S, Hamada H, Reddy P and Kakunaga T, 1985, Molecular structure of the human cytoplasmic β-actin gene; interspecies homology of sequences in the introns. Proc Natl Acad Sci, USA, 82, 6133-7.
11. Fukunaga R, Seto Y, Mizushima S and Ngata S, 1990, Three different mRNAs encoding human granulocyte colony-stimulating factor receptor. Proc Natl Acad Sci, USA, 87, 8702-6.
12. Riccio A, Grimaldi G, Verde P, et al. 1985, The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res, 13, 2759-71.
13. Niedbala MJ and Picarella MS, 1991, Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by γ-interferon. Blood, 79, 678-87.
14. Laug, WE, Cao XR, Yu YB, et al. 1993, Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res, 53, 6051-7.
15. Baker MS, Bleakley P, Woodrow GC and Doe WF, 1990, Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res, 50, 4676-84.
16. Cajot JF, Bamat J, Bergonzelli GE, et al. 1990, Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci, USA, 87, 6939-43.
17. Laug WE, 1985, Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells. J Natl Inst Cancer, 75, 345-52.
18. Cross M and Dexter TM, 1991, Growth factors in development, transformation, and tumorigenesis. Cell, 64, 271-80.
19. Nishizawa M, Tsuchiya M, Watanabe-Fukunaga R and Nagata S, 1990, Multiple elements in the promotor of granulocyte colony-stimulating factor gene regulate its constitutive expression in human carcinoma cells. J Biol Chem, 265, 5897-902.
20. Tachibana M, Miyakawa A, Tazaki H, et al. 1995, Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res, 55, 3438-43.
21. Satoh H, Abe Y, Katoh Y, et al. 1993, Bladder carcinoma producing granulocyte colony-stimulating factor: a case report. J Urol, 149, 843-5.
22. Safarians S, Rivera SP, Sternlicht MD, et al. 1997, Ectopic G-CSF expression in human melanoma lines marks a trans-dominant pathway of tumor progression. Am J Pathol, 150, 949-62.
23. Dano K, Andreasen PA, Grondahl-Hansen J, et al. 1985, Plasminogen activators, tissue degradation and cancer. Adv Cancer Res, 44, 139-266.
24. Hart PH, Vitti GF, Burgess DR, et al. 1991, Activation of human monocytes by granulocyte-macrophage colony-stimulating factor: increased urokinase-type plasminogen activator activity. Blood, 77, 841-8.
25. Stacey KJ, Fowles LF, Colman MS, et al. 1995, Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. Mol Cell Biol, 15, 3430-41.
26. Keski-Oja J, Lohi J, Tuuttila A, et al. 1992, Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res, 202, 471-6.
27. Schultz RM, Yu H and Zhang JY, 1992, The role of urokinase and urokinase inhibitor in tumor cell metastasis. Fibrinolysis, 6, 23-9.